Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
95% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ATRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATRS' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 9999.50 Max: No Debt
Current: No Debt
Equity to Asset 0.79
ATRS's Equity to Asset is ranked higher than
77% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ATRS: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
ATRS' s Equity to Asset Range Over the Past 10 Years
Min: -4.09  Med: 0.52 Max: 0.94
Current: 0.79
-4.09
0.94
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
97% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.00 vs. ATRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 2.48
M-Score: -1.01
WACC vs ROIC
7.62%
-126.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -44.82
ATRS's Operating margin (%) is ranked lower than
82% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. ATRS: -44.82 )
Ranked among companies with meaningful Operating margin (%) only.
ATRS' s Operating margin (%) Range Over the Past 10 Years
Min: -215.47  Med: -105.58 Max: -26.96
Current: -44.82
-215.47
-26.96
Net-margin (%) -45.25
ATRS's Net-margin (%) is ranked lower than
79% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. ATRS: -45.25 )
Ranked among companies with meaningful Net-margin (%) only.
ATRS' s Net-margin (%) Range Over the Past 10 Years
Min: -224.17  Med: -104.33 Max: -26.66
Current: -45.25
-224.17
-26.66
ROE (%) -35.21
ATRS's ROE (%) is ranked lower than
81% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. ATRS: -35.21 )
Ranked among companies with meaningful ROE (%) only.
ATRS' s ROE (%) Range Over the Past 10 Years
Min: -280.93  Med: -69.41 Max: -19.42
Current: -35.21
-280.93
-19.42
ROA (%) -26.69
ATRS's ROA (%) is ranked lower than
78% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. ATRS: -26.69 )
Ranked among companies with meaningful ROA (%) only.
ATRS' s ROA (%) Range Over the Past 10 Years
Min: -91.53  Med: -38.32 Max: -15.37
Current: -26.69
-91.53
-15.37
ROC (Joel Greenblatt) (%) -137.61
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. ATRS: -137.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2034.35  Med: -942.81 Max: -151.84
Current: -137.61
-2034.35
-151.84
Revenue Growth (3Y)(%) 14.90
ATRS's Revenue Growth (3Y)(%) is ranked higher than
87% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ATRS: 14.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.8  Med: 5.30 Max: 26.5
Current: 14.9
-53.8
26.5
EBITDA Growth (3Y)(%) 8.10
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. ATRS: 8.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.5  Med: -10.60 Max: 80.8
Current: 8.1
-41.5
80.8
EPS Growth (3Y)(%) 10.70
ATRS's EPS Growth (3Y)(%) is ranked higher than
61% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ATRS: 10.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.2  Med: -9.40 Max: 81.5
Current: 10.7
-58.2
81.5
» ATRS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ATRS Guru Trades in Q1 2015

First Eagle Investment 20,000 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

ATRS Guru Trades in Q2 2015

Jim Simons 182,941 sh (New)
First Eagle Investment 20,000 sh (unchged)
» More
Q3 2015

ATRS Guru Trades in Q3 2015

Jim Simons 289,041 sh (+58.00%)
First Eagle Investment 20,000 sh (unchged)
» More
Q4 2015

ATRS Guru Trades in Q4 2015

Paul Tudor Jones 14,685 sh (New)
Chuck Royce 97,284 sh (New)
Jim Simons 1,385,438 sh (+379.32%)
First Eagle Investment 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.54
ATRS's P/B is ranked higher than
52% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. ATRS: 2.54 )
Ranked among companies with meaningful P/B only.
ATRS' s P/B Range Over the Past 10 Years
Min: 1.64  Med: 8.08 Max: 86.11
Current: 2.54
1.64
86.11
P/S 3.48
ATRS's P/S is ranked lower than
59% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ATRS: 3.48 )
Ranked among companies with meaningful P/S only.
ATRS' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 12.52 Max: 32.73
Current: 3.48
2.25
32.73
Current Ratio 3.93
ATRS's Current Ratio is ranked higher than
73% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.64 vs. ATRS: 3.93 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.64 Max: 14.51
Current: 3.93
0.21
14.51
Quick Ratio 3.59
ATRS's Quick Ratio is ranked higher than
77% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ATRS: 3.59 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.52 Max: 14.09
Current: 3.59
0.21
14.09
Days Inventory 107.31
ATRS's Days Inventory is ranked higher than
63% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.92 vs. ATRS: 107.31 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s Days Inventory Range Over the Past 10 Years
Min: 11.13  Med: 29.50 Max: 200.11
Current: 107.31
11.13
200.11
Days Sales Outstanding 63.57
ATRS's Days Sales Outstanding is ranked higher than
50% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.57 vs. ATRS: 63.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.3  Med: 52.28 Max: 86.08
Current: 63.57
18.3
86.08
Days Payable 97.32
ATRS's Days Payable is ranked higher than
70% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. ATRS: 97.32 )
Ranked among companies with meaningful Days Payable only.
ATRS' s Days Payable Range Over the Past 10 Years
Min: 85.36  Med: 158.69 Max: 380
Current: 97.32
85.36
380

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.50
ATRS's Price/Net Cash is ranked higher than
69% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.72 vs. ATRS: 5.50 )
Ranked among companies with meaningful Price/Net Cash only.
ATRS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.06  Med: 12.27 Max: 85
Current: 5.5
2.06
85
Price/Net Current Asset Value 3.55
ATRS's Price/Net Current Asset Value is ranked higher than
71% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. ATRS: 3.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.8  Med: 10.38 Max: 34
Current: 3.55
1.8
34
Price/Tangible Book 2.68
ATRS's Price/Tangible Book is ranked higher than
60% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.11 vs. ATRS: 2.68 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.56  Med: 8.13 Max: 30.36
Current: 2.68
1.56
30.36
Price/Median PS Value 0.28
ATRS's Price/Median PS Value is ranked higher than
95% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ATRS: 0.28 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.75 Max: 2.25
Current: 0.28
0.08
2.25
Earnings Yield (Greenblatt) (%) -16.70
ATRS's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ATRS: -16.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -33.02  Med: 0.00 Max: 0
Current: -16.7
-33.02
0

More Statistics

Revenue(Mil) $46
EPS $ -0.14
Beta0.77
Short Percentage of Float7.95%
52-Week Range $0.67 - 2.75
Shares Outstanding(Mil)154.85

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 55 78
EPS($) 0.01 0.05
EPS without NRI($) 0.01 0.05

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:UTMD, TSE:4218, TSX:CRH, OSTO:BIOT, ROCO:6499, TSX:TOS » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.
» More Articles for NAS:ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
Antares Pharma to Present at the Deutsche Bank Securities,INC 41st Annual Healthcare Conference Apr 27 2016
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 41st Annual Health Care Conference Apr 27 2016
OTREXUP.COM Website Awarded a Bronze Horizon Interactive Award Apr 25 2016
4 Trending Small Cap Stocks Making Big Moves Today Apr 22 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Apr 15 2016
New Strong Sell Stocks for April 6th Apr 06 2016
Antares Pharma Discloses Pen 1 Development Project as Teriparatide Apr 05 2016
Antares Pharma Discloses “Pen 1” Development Project as Teriparatide Apr 05 2016
New Strong Sell Stocks for March 31st Mar 31 2016
Additional Dosage Strengths of Otrexup™ (methotrexate) Injection Approved by FDA Mar 29 2016
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016
Five Penny Stocks To Buy Based on Smart Money Sentiment Mar 26 2016
OraSure Technologies Appoints Eamonn P. Hobbs to its Board of Directors Mar 23 2016
Falling Earnings Estimates Signal Weakness Ahead for Antares Pharma (ATRS) Mar 18 2016
Antares Pharma Announces Completion of the 52 Week QuickShot® Phase 3 Study in Testosterone... Mar 16 2016
ANTARES PHARMA, INC. Financials Mar 12 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 10 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 09 2016
Edited Transcript of ATRS earnings conference call or presentation 8-Mar-16 1:30pm GMT Mar 08 2016
Antares Pharma (ATRS) Stock Lower on Q4 Results Mar 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK